© 2023 Peel Therapeutics | All rights reserved |
Who we are
Peel Therapeutics is on an expedition to unlock nature’s secrets and overcome life-threatening conditions. These evolutionary outliers rarely make their way to patients, and we are determined to change that.
We are an evolutionary-inspired, clinical-stage biotech company developing medicines to transform patients’ lives. Peel (the Hebrew word for “elephant”) launched with our focus on cancer-fighting proteins in elephants and we quickly recognized the power of using evolution’s solutions to treat and prevent disease. In addition to developing elephant p53 (EP53) nanoparticles for the treatment of cancer, our team is advancing additional therapies derived from nature’s superabilities to treat cancer and inflammation.
Our Approach
Life science R&D has produced countless new therapies with positive health outcomes, but it cannot compare to ages of evolutionary history. We seek out distinct proteins and molecules in nature that have exceeded what we thought was biologically possible. We then apply our expertise and technology to rapidly translate this evolutionary biology and advance our therapeutic pipeline to treat a spectrum of devastating conditions, including cancer and inflammation. Our therapy’s efficacy is derived from its distinctive biological structure, which enables it to accumulate in disease-relevant cells and interfere only with disease processes— to maximize impact while minimizing side-effects.
Our Mission
Peel Therapeutics’ mission is to engineer evolutionary biology to improve patient lives.
Our Vision
Peel Therapeutics aims to develop safe and highly effective medicines that transform patient care.
Our Leadership
Our multidisciplinary team across the US and Israel offers a unique blend of scientific and medical expertise, enthusiasm and curiosity. We hail from all corners of industry, academia, and clinical medicine, and the patients we serve are the driving force behind the work we do every day.